Group 1 - The article discusses the author's long position in the shares of GRFS and UNM, indicating a positive outlook on these companies [1] - It emphasizes the importance of conducting due diligence and research before making any investment decisions, particularly for short-term trading and options trading [2] - The article clarifies that past performance is not indicative of future results, and no specific investment recommendations are provided [3]

Core Viewpoint - Shanghai Laishi (002252.SZ) has seen its controlling shareholder, Haiyingkang (Qingdao) Medical Technology Co., Ltd., announce a third share buyback plan within six months, reflecting confidence in the company's future development and long-term investment value [1] Group 1: Share Buyback Plans - Haiyingkang plans to increase its stake in Shanghai Laishi by investing between 250 million to 500 million yuan over the next six months, with no price range set for the buyback [1] - The buyback will be funded through self-owned funds and a special loan for share buyback, with the loan covering no more than 90% of the total amount [1] - China Bank has agreed to provide Haiyingkang a special loan of up to 450 million yuan for the share buyback, with a loan term of three years [1] Group 2: Historical Context of Shareholding - This marks the third buyback plan since Haiyingkang acquired control of Shanghai Laishi in early 2024, when it took over 1.766 billion shares, representing 26.58% of the total share capital [1][2] - Haiyingkang has previously completed two rounds of share buybacks, accumulating a total of 72.43 million shares (1.09% of total shares) for approximately 497 million yuan in the first round and 73.04 million shares (1.1% of total shares) for about 500 million yuan in the second round [2] Group 3: Current Shareholding Structure - After the completion of the three rounds of buybacks, Haiyingkang is expected to have invested nearly 1.5 billion yuan in total [3] - Currently, Haiyingkang directly holds 1.475 billion shares (22.21% of total shares) and controls an additional 437 million shares (6.58% of total shares) through voting rights entrusted by Grifols, S.A., totaling 1.912 billion shares (28.80% of total shares) [3] Group 4: Company Performance - Shanghai Laishi is one of China's largest blood product manufacturers, operating 44 plasma collection stations across 11 provinces [3] - In 2024, the company achieved a record plasma collection volume exceeding 1,600 tons, with total revenue of 8.176 billion yuan, a year-on-year increase of 2.67%, and a net profit of 2.193 billion yuan, reflecting a year-on-year growth of 23.25% [3]

Core Viewpoint - Grifols (GRFS) is currently positioned as a better value opportunity compared to Neurocrine Biosciences (NBIX) based on various valuation metrics and earnings outlook [1][3]. Valuation Metrics - GRFS has a forward P/E ratio of 7.65, significantly lower than NBIX's forward P/E of 31.35, indicating that GRFS may be undervalued [5]. - The PEG ratio for GRFS is 0.26, while NBIX's PEG ratio is 1.22, suggesting that GRFS has a more favorable earnings growth outlook relative to its price [5]. - GRFS's P/B ratio stands at 0.60, compared to NBIX's P/B of 4.63, further highlighting GRFS's relative undervaluation [6]. Earnings Outlook - GRFS has a Zacks Rank of 2 (Buy), indicating a stronger improvement in its earnings outlook compared to NBIX, which has a Zacks Rank of 3 (Hold) [3][6]. - The overall valuation metrics and solid earnings outlook position GRFS as the superior value option in the current market [6].

Company Overview - Grifols conducted a conference call to review its Business Results for the First Quarter of 2025, featuring key executives including the CEO, CFO, and President of Biopharma [1]. Logistics and Presentation - The conference call is expected to last about an hour, including a Q&A session, and is being recorded for future reference [2]. - Additional materials, including the presentation, are available on the Grifols Investor Relations website [2]. Financial Reporting - All financial statements are prepared in accordance with EU IFRS and other applicable reporting provisions, including alternative performance measures (APMs) [4]. - Grifols management utilizes APMs to assess financial performance, cash flow, and overall business health [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-35193 Grifols, S.A. (Translation of registrant's name into English) Avinguda de la Generalitat, 152-158 Parc de Negocis Can Sant Joan Sant Cugat del Valles 08174 Barcelona, Spain (Address of registrant's principal executive office) Indicate by check mark whether the regis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-35193 Grifols, S.A. Form 20-F x Form 40-F ¨ G r i fo l s, S.A. TABLE OF CONTE N T S S e q u e n t i a l P a g e N u m b e r 1. E a rn i n g s P r e s s R e l e a s e , d a t e d M a y 1 2, 2 0 2 5 2. Q 1 2 0 2 5 E a rn i n g s P r e s e n t a t i o n 3 5 (Translation of r ...

Core Viewpoint - ADMA Biologics has demonstrated strong performance in 2024, with continued growth expected in 2025, driven by its lead product Asceniv and new supply contracts [1][8]. Financial Performance - In Q4 2024, ADMA reported adjusted earnings per share of 14 cents, slightly missing the Zacks Consensus Estimate by one cent, while revenues reached $118 million, surpassing the consensus estimate of $112 million [1]. - The company has revised its financial targets, now expecting revenues of over $490 million in 2025 and $605 million in 2026, with net income projected to exceed $175 million in 2025 and $235 million in 2026 [9]. Product and Market Analysis - ADMA Biologics specializes in plasma-derived biologics for treating immune deficiencies and preventing infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [3][4]. - Asceniv, the lead product, is a plasma-derived IVIG designed for treating primary immunodeficiency disease (PIDD) and is manufactured using a patented plasma donor screening methodology [5][6]. - Strong demand for Asceniv is anticipated to continue into 2025, with expectations for increased patient starts and market penetration [7]. Supply Chain and Growth Potential - ADMA has entered into long-term high-titer plasma supply contracts, significantly increasing its access to raw material plasma, with a five-fold increase in total collection capacity from approximately 250 collection centers [8]. - Management projects that these supply agreements could position ADMA to achieve $1 billion in total annual revenues before 2030, indicating substantial growth potential in the 2030s [8]. Competitive Landscape - ADMA Biologics competes with Takeda and Grifols in the U.S. market for plasma-derived products, with a targeted market that shows significant growth potential [10].